Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $248,203.24 in Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Sarepta Therapeutics Trading Down 1.2 %

Shares of NASDAQ SRPT opened at $97.19 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 52-week low of $97.06 and a 52-week high of $173.25. The firm has a 50 day moving average price of $111.73 and a two-hundred day moving average price of $119.96. The stock has a market cap of $9.43 billion, a P/E ratio of 77.75 and a beta of 0.79.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after acquiring an additional 117,904 shares during the period. Capital International Investors increased its position in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Janus Henderson Group PLC increased its position in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares during the period. Farallon Capital Management LLC increased its position in Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after acquiring an additional 285,100 shares during the period. Finally, Wellington Management Group LLP increased its position in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after acquiring an additional 665,087 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Piper Sandler cut their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price objective for the company. Royal Bank of Canada cut their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, Scotiabank assumed coverage on shares of Sarepta Therapeutics in a report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $170.41.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.